Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABEO NASDAQ:COLL NASDAQ:LENZ NASDAQ:XNCR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABEOAbeona Therapeutics$5.42+0.2%$6.09$3.93▼$7.54$277.94M1.421.00 million shs1.03 million shsCOLLCollegium Pharmaceutical$35.54-0.5%$36.16$23.23▼$39.95$1.12B0.65373,988 shs188,398 shsLENZLENZ Therapeutics$31.38-4.0%$40.91$16.53▼$50.40$894.96M0.5395,784 shs1.10 million shsXNCRXencor$12.34-7.1%$10.24$6.92▼$27.24$880.09M0.96864,137 shs1.29 million shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABEOAbeona Therapeutics-1.10%-2.17%-1.28%-18.65%-17.66%COLLCollegium Pharmaceutical+0.99%+8.61%+0.20%+11.21%-1.33%LENZLENZ Therapeutics-2.56%-21.86%-20.75%-2.10%+32.55%XNCRXencor-8.41%-5.74%+27.91%+43.83%-37.40%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABEOAbeona Therapeutics$5.42+0.2%$6.09$3.93▼$7.54$277.94M1.421.00 million shs1.03 million shsCOLLCollegium Pharmaceutical$35.54-0.5%$36.16$23.23▼$39.95$1.12B0.65373,988 shs188,398 shsLENZLENZ Therapeutics$31.38-4.0%$40.91$16.53▼$50.40$894.96M0.5395,784 shs1.10 million shsXNCRXencor$12.34-7.1%$10.24$6.92▼$27.24$880.09M0.96864,137 shs1.29 million shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABEOAbeona Therapeutics-1.10%-2.17%-1.28%-18.65%-17.66%COLLCollegium Pharmaceutical+0.99%+8.61%+0.20%+11.21%-1.33%LENZLENZ Therapeutics-2.56%-21.86%-20.75%-2.10%+32.55%XNCRXencor-8.41%-5.74%+27.91%+43.83%-37.40%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABEOAbeona Therapeutics 2.83Moderate Buy$19.50259.78% UpsideCOLLCollegium Pharmaceutical 3.00Buy$42.3319.11% UpsideLENZLENZ Therapeutics 2.67Moderate Buy$54.8074.63% UpsideXNCRXencor 2.64Moderate Buy$24.2296.29% UpsideCurrent Analyst Ratings BreakdownLatest ABEO, LENZ, COLL, and XNCR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/20/2025LENZLENZ TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$40.00 ➝ $50.0010/14/2025XNCRXencorWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/13/2025ABEOAbeona TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.0010/10/2025LENZLENZ TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$67.0010/8/2025ABEOAbeona TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C-)10/8/2025COLLCollegium PharmaceuticalWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)10/8/2025LENZLENZ TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025XNCRXencorCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy10/6/2025XNCRXencorCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$40.009/27/2025ABEOAbeona TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C-)9/27/2025COLLCollegium PharmaceuticalWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)(Data available from 10/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABEOAbeona Therapeutics$3.50M79.41N/AN/A$1.01 per share5.37COLLCollegium Pharmaceutical$631.45M1.77$12.43 per share2.86$7.10 per share5.01LENZLENZ TherapeuticsN/AN/AN/AN/A$7.42 per shareN/AXNCRXencor$110.49M7.97N/AN/A$9.63 per share1.28Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABEOAbeona Therapeutics-$63.73M$0.707.74N/AN/AN/A89.05%45.64%11/13/2025 (Estimated)COLLCollegium Pharmaceutical$69.19M$1.0434.175.90N/A5.13%97.28%13.87%11/6/2025 (Estimated)LENZLENZ Therapeutics-$49.77M-$1.90N/AN/AN/AN/A-25.63%-24.43%11/5/2025 (Estimated)XNCRXencor-$232.62M-$2.40N/AN/AN/A-121.52%-25.75%-18.19%11/5/2025 (Estimated)Latest ABEO, LENZ, COLL, and XNCR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/13/2025Q3 2025ABEOAbeona Therapeutics-$0.27N/AN/AN/A$5.53 millionN/A11/6/2025Q3 2025COLLCollegium Pharmaceutical$1.89N/AN/AN/A$191.25 millionN/A11/5/2025Q3 2025LENZLENZ Therapeutics-$0.67N/AN/AN/AN/AN/A11/5/2025Q3 2025XNCRXencor-$0.72N/AN/AN/A$29.73 millionN/A8/14/2025Q2 2025ABEOAbeona Therapeutics-$0.39$1.71+$2.10$1.71$21.71 million$0.40 million8/6/2025Q2 2025XNCRXencor-$0.78-$0.41+$0.37-$0.41$22.59 million$43.61 million7/30/2025Q2 2025LENZLENZ Therapeutics-$0.58-$0.53+$0.05-$0.53$5.00 million$5.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABEOAbeona TherapeuticsN/AN/AN/AN/AN/ACOLLCollegium PharmaceuticalN/AN/AN/AN/AN/ALENZLENZ TherapeuticsN/AN/AN/AN/AN/AXNCRXencorN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABEOAbeona Therapeutics0.096.736.65COLLCollegium Pharmaceutical3.271.181.10LENZLENZ TherapeuticsN/A20.5420.54XNCRXencorN/A5.345.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABEOAbeona Therapeutics80.56%COLLCollegium PharmaceuticalN/ALENZLENZ Therapeutics54.32%XNCRXencorN/AInsider OwnershipCompanyInsider OwnershipABEOAbeona Therapeutics6.90%COLLCollegium Pharmaceutical2.51%LENZLENZ Therapeutics6.90%XNCRXencor4.76%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABEOAbeona Therapeutics9051.28 million47.74 millionOptionableCOLLCollegium Pharmaceutical21031.50 million30.71 millionOptionableLENZLENZ Therapeutics11028.52 million26.55 millionN/AXNCRXencor28071.32 million67.93 millionOptionableABEO, LENZ, COLL, and XNCR HeadlinesRecent News About These CompaniesXencor to Host Webcast and Conference Call to Discuss Initial Results from the Ongoing Phase 1 Dose-Escalation Study of XmAb819 in Advanced Clear Cell Renal Cell CarcinomaOctober 21 at 8:01 AM | businesswire.comStocks Showing Improving Market Leadership: Xencor Earns 83 RS RatingOctober 17, 2025 | msn.comAberdeen Group plc Grows Stock Position in Xencor, Inc. $XNCROctober 17, 2025 | marketbeat.comXencor Stock Earns Relative Strength Rating UpgradeOctober 16, 2025 | msn.comXencor (NASDAQ:XNCR) Earns Sell (D-) Rating from Weiss RatingsOctober 16, 2025 | americanbankingnews.comXencor (NASDAQ:XNCR) Shares Up 10% - Should You Buy?October 15, 2025 | marketbeat.comXencor Announces Presentation of Initial Phase 1 Dose-Escalation Results of XmAb819 in Clear Cell Renal Cell Carcinoma at the AACR-NCI-EORTC International Conference on ...October 14, 2025 | finance.yahoo.comXencor price target raised to $14 from $12 at BofAOctober 14, 2025 | msn.comXencor slides amid plans for early-stage trial data for kidney cancer drugOctober 14, 2025 | msn.comXencor (NASDAQ:XNCR) Trading Down 13.3% - Should You Sell?October 14, 2025 | marketbeat.comXencor (NASDAQ:XNCR) Receives "Sell (D-)" Rating from Weiss RatingsOctober 14, 2025 | marketbeat.comXencor Announces Presentation of Initial Phase 1 Dose-Escalation Results of XmAb819 in Clear Cell Renal Cell Carcinoma at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsOctober 14, 2025 | businesswire.comXencor Sees RS Rating Rise To 73October 13, 2025 | msn.comAnalysts Offer Predictions for Xencor FY2025 EarningsOctober 12, 2025 | americanbankingnews.comEquities Analysts Issue Forecasts for Xencor FY2025 EarningsOctober 11, 2025 | marketbeat.comXencor, Inc. (NASDAQ:XNCR) Given Average Rating of "Moderate Buy" by AnalystsOctober 11, 2025 | marketbeat.comXencor (NASDAQ:XNCR) Raised to Strong-Buy at Cantor FitzgeraldOctober 10, 2025 | marketbeat.comCantor Fitzgerald Forecasts Xencor FY2025 EarningsOctober 7, 2025 | marketbeat.comXencor (NASDAQ:XNCR) Given "Overweight" Rating at Cantor FitzgeraldOctober 6, 2025 | marketbeat.comXencor (NASDAQ:XNCR) Trading 6.2% Higher - Should You Buy?September 26, 2025 | marketbeat.comXencor: Bispecific Antibody Program Takes Shape With Q4 Data ReleaseSeptember 19, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025October’s Top 5 Stocks Poised for Big BreakoutsBy Thomas Hughes | October 1, 2025Costco Investors Will Get a “Special” Treat for ChristmasBy Thomas Hughes | September 29, 2025Datavault AI: The New AI Contender Backed by Big FundingBy Jeffrey Neal Johnson | October 1, 2025Bassett Furniture: Buy Now, Sit Back, and Collect DividendsBy Thomas Hughes | October 11, 2025ABEO, LENZ, COLL, and XNCR Company DescriptionsAbeona Therapeutics NASDAQ:ABEO$5.42 +0.01 (+0.18%) Closing price 04:00 PM EasternExtended Trading$5.46 +0.04 (+0.65%) As of 04:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.Collegium Pharmaceutical NASDAQ:COLL$35.54 -0.17 (-0.48%) Closing price 04:00 PM EasternExtended Trading$35.53 -0.01 (-0.03%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.LENZ Therapeutics NASDAQ:LENZ$31.38 -1.32 (-4.04%) Closing price 04:00 PM EasternExtended Trading$31.70 +0.32 (+1.02%) As of 05:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.Xencor NASDAQ:XNCR$12.34 -0.95 (-7.15%) Closing price 04:00 PM EasternExtended Trading$12.38 +0.04 (+0.32%) As of 05:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Capital One Just Flashed a Buy Signal—New Highs Could Be Next Why Intuitive Surgical Is a No-Brainer for Long-Term Investors Is Oracle’s AI Rally Over? Wall Street Thinks ORCL Could Hit $400 GM Posts Largest Gain Since the Pandemic: Shares Still Look Cheap 3 Pharmaceutical Growth Stocks to Buy and Hold for 10 Years Why Micron Stock Could Soar 35% on AI Memory Demand WesBanco Insiders Signal Confidence With Coordinated Buys Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
